Legato Capital Management LLC Argenx Se Transaction History

Legato Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 16, 2024	SELL	$338.91 - $506.01 $164,710 - $245,920	-486 Reduced 29.63%	1,154 $439,000
Q3 2023 Oct 12, 2023	BUY	$369.35 - $548.43 $605,734 - $899,425	1,640 New	1,640 $806,000
Q2 2023 Aug 17, 2023	SELL	$360.14 - $422.58 $284,150 - $333,415	-789 Reduced 27.48%	2,082 $811,000
Q4 2022 Feb 01, 2023	BUY	$342.17 - $402.31 $982,370 - $1.16 Million	2,871 New	2,871 $1.09 Million
Q3 2021 Nov 09, 2021	SELL	$295.0 - $350.58 $350,755 - $416,839	-1,189 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$257.11 - $319.92 $305,703 - $380,384	1,189 New	1,189 $358,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Legato Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Legato Capital Management LLC with notifications on news.